Skip to main content
Explore URMC
menu

Standard Combination Therapy with Niraparib in Treating Patients with Prostate Cancer

Research Question:
What are the side effects and best dose of the drug, niraparib, in treating patients with prostate cancer that has a high chance of coming back (high risk)?

Basic Study Information

Purpose:
This phase II trial studies the side effects and best dose of niraparib, and to see how well it works in combination with standard of care radiation therapy and hormonal therapy (androgen deprivation therapy) in treating patients with prostate cancer that has a high chance of coming back (high risk). Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding niraparib to the usual treatments of radiation therapy and hormonal therapy may lower the chance of prostate cancer growing or returning.

Location: University of Rochester Medical Center
Study Reference #: CGUP19100

Lead Researcher (Principal Investigator)

Lead Researcher:  Hong Zhang

Study Contact Information

Study Coordinator: Liana Gonsalves
Phone: (585) 275-7848
Email: Liana_Gonsalves@URMC.Rochester.edu

Additional Study Details

Return to Search